umbilical cord Wharton's jelly-derived human MSC / Public Assistance - Paris Hospitals - LARVOL DELTA

STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - P1/2 | N=47 | Completed | Sponsor: Assistance Publique - Hôpitaux de Paris | Active, not recruiting ➔ Completed | Trial primary completion date: Nov 2020 ➔ Oct 2021

Trial completion • Trial primary completion date • Acute Respiratory Distress Syndrome • Congestive Heart Failure • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • CXCL8 • IL10 • IL6 • TGFB1 • TNFA

STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - P1/2; N=47; Active, not recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; Trial completion date: Apr 2022 ➔ Nov 2021

Trial completion date • Acute Respiratory Distress Syndrome • Congestive Heart Failure • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • CXCL8 • IL10 • IL6 • TGFB1 • TNFA

STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - P1/2; N=47; Active, not recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; Recruiting ➔ Active, not recruiting; Trial primary completion date: Apr 2021 ➔ Jan 2021

Enrollment closed • Trial primary completion date • Acute Respiratory Distress Syndrome • Congestive Heart Failure • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • ANGPT2 • CXCL8 • IL10 • IL6 • TGFB1 • TNFA

STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - P1/2; N=40; Recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; Trial completion date: Jul 2021 ➔ Apr 2022; Trial primary completion date: Aug 2020 ➔ Apr 2021

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Congestive Heart Failure • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • ANGPT2 • CXCL8 • IL10 • IL6 • TNFA

STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - P1/2; N=40; Recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; N=60 ➔ 40

Enrollment change • Acute Respiratory Distress Syndrome • Congestive Heart Failure • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; Not yet recruiting ➔ Recruiting

Enrollment open